{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:33:27Z","timestamp":1764603207562},"reference-count":30,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Pharm. Sci."],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:p>The purpose of this study is to develop and improve oral liquids formulations of sildenafil citrate for paediatric use. Four different formulations were developed, which are as follows: two aqueous solutions of sildenafil citrate (2.5 mg\/mL), with or without preservatives, and two other solutions of sildenafil in simple syrup (1.25 mg\/mL), with or without preservatives. All of the formulations were physically, chemically and microbiologically stable for three months. The results of the stability studies allowed for the optimisation of formulations without preservatives due to their simplicity and their similar stable conditions when compared to the formulations containing antimicrobials. The shelf life of both formulations was three months; however, upon opening, aqueous solutions should be used within 10 days and kept refrigerated, and syrup solutions should be used within 14 days in a hospital setting.<\/jats:p>","DOI":"10.1590\/s1984-82502013000200021","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T14:07:07Z","timestamp":1374934027000},"page":"381-388","source":"Crossref","is-referenced-by-count":5,"title":["Development and stability assessment of liquid paediatric formulations containing sildenafil citrate"],"prefix":"10.1590","volume":"49","author":[{"given":"F\u00e1tima","family":"Roque","sequence":"first","affiliation":[{"name":"Polytechnic Institute of Guarda; University of Coimbra"}]},{"given":"Ana Cristina","family":"Rama","sequence":"additional","affiliation":[{"name":"University of Coimbra; University of Coimbra Hospital"}]},{"given":"Jo\u00e3o Jos\u00e9","family":"Sousa","sequence":"additional","affiliation":[{"name":"University of Coimbra"}]},{"given":"Maria Eug\u00e9nia","family":"Pina","sequence":"additional","affiliation":[{"name":"University of Coimbra"}]}],"member":"530","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1542\/peds.99.2.268","article-title":"Committee on drugs: \"Inactive\" ingredients in pharmaceutical products: update (subject review","volume":"99","year":"1997","journal-title":"Pediatrics","ISSN":"http:\/\/id.crossref.org\/issn\/0031-4005","issn-type":"print"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/vhrm.2006.2.4.411","article-title":"Sildenafil in the treatment of pulmonary hypertension","volume":"2","author":"BARNETT C.F.","year":"2006","journal-title":"Vasc. Health Risk. Manag."},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1651-2227.2003.tb00583.x","article-title":"Extemporaneous (magistral) preparation of oral medicines for children in European hospitals","volume":"92","author":"BRION F.","year":"2003","journal-title":"Acta Paediatr."},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-006-0193-0","article-title":"Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years","volume":"62","author":"CECI A.","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref5","series-title":"Note for guidance on excipients, antioxidants and antimicrobial preservatives, in the dossier for application for marketing authorization of medicinal products (CPMP\/QWP\/419\/03)"},{"key":"ref6","series-title":"Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products"},{"key":"ref7","series-title":"Note for Guidance on In-use Stability Testing of Human Medicinal Products","year":"2001"},{"key":"ref8","article-title":"Regulation (EC) No. 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use","year":"2006","journal-title":"Official Journal of the European Union"},{"key":"ref9","series-title":"Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate","year":"2009"},{"key":"ref10","series-title":"Reflection paper: formulations of choice for the paediatric population","year":"2006"},{"key":"ref11","series-title":"EUROPEAN Pharmacopoeia","first-page":"157","year":"2005","edition":"5"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1695-4033(04)78449-0","article-title":"Oral sildenafil: a promising drug for persistent neonatal pulmonary hypertension","volume":"61","author":"GONZALEZ N.F.","year":"2004","journal-title":"An. Pediatr. (Barc)."},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1345\/aph.1H611","article-title":"Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids","volume":"41","author":"GHULAM A.","year":"2007","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"ref14","first-page":"398","article-title":"Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products","volume":"9","author":"GLASS B.D.","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2125.2005.02327.x","article-title":"Effect of the pediatric exclusivity provision on children\u00b4s access to medicines","volume":"59","author":"GRIEVE J.","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"24","key":"ref16","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1161\/CIRCULATIONAHA.104.473371","article-title":"Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study","volume":"111","author":"HUMPL T.","year":"2005","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"issue":"7349","key":"ref17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/bmj.324.7349.1313","article-title":"Unlicensed and off label prescription of drugs to children: Population based cohort study","volume":"324","author":"JONG G.W.","year":"2002","journal-title":"BMJ Br. Med. J."},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/157488607779315471","article-title":"Quality, safety and efficacy in the 'off-label' use of medicines","volume":"2","author":"KAIRUZ T.E.","year":"2007","journal-title":"Curr. Drug Saf."},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/01.PCC.0000113266.26638.AD","article-title":"Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia","volume":"5","author":"KELLER R.L.","year":"2004","journal-title":"Pediatr. Crit. Care Med."},{"issue":"4","key":"ref20","first-page":"404","article-title":"Chronic oral sildenafil therapy in severe pulmonary artery hypertension","volume":"54","author":"KOTHARI S.S.","year":"2002","journal-title":"Indian Heart J."},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1164\/rccm.200503-510OC","article-title":"Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury","volume":"172","author":"LADHA F.","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003495-200767010-00005","article-title":"Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension","volume":"67","author":"LEIBOVITCH L.","year":"2007","journal-title":"Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1695-4033(03)78161-2","article-title":"Sildenafil in the treatment of pulmonary hypertension","volume":"59","author":"MART\u00cdNEZ E.G.","year":"2003","journal-title":"An. Pediatr. (Barc)"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2146\/ajhp050208","article-title":"Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children","volume":"63","author":"NAHATA M.C.","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1164\/rccm.200605-694OC","article-title":"Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children","volume":"174","author":"NAMACHIVAYAM P.","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00431-005-1698-8","article-title":"A literature review on off-label drug use in children","volume":"164","author":"PANDOLFINI C.","year":"2005","journal-title":"Eur. J. Pediatr.","ISSN":"http:\/\/id.crossref.org\/issn\/0340-6199","issn-type":"print"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1542\/peds.111.2.291","article-title":"Risk factors for unlicensed and off-Label drug use in children outside the hospital","volume":"111","author":"SCHIRM E.","year":"2003","journal-title":"Pediatrics","ISSN":"http:\/\/id.crossref.org\/issn\/0031-4005","issn-type":"print"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0278-6915(00)00162-9","article-title":"Safety assessment of propyl paraben: a review of the published literature","volume":"39","author":"SONI M.G.","year":"2001","journal-title":"Food Chem. Toxicol."},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0278-6915(02)00107-2","article-title":"Evaluation of the health aspects of methyl paraben: A review of the published literature","volume":"40","author":"SONI M.G.","year":"2002","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00228-008-0560-0","article-title":"Off-label use of medicines in children: Can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease","volume":"65","author":"TAFURI G.","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Brazilian Journal of Pharmaceutical Sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjps\/v49n2\/21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T14:26:35Z","timestamp":1495895195000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1984-82502013000200021&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1984-82502013000200021"],"URL":"https:\/\/doi.org\/10.1590\/s1984-82502013000200021","relation":{},"ISSN":["1984-8250"],"issn-type":[{"value":"1984-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}